Cleared Special

K162959 - LIAISON® EA IgG and LIAISON® EA IgG Serum Control Set (FDA 510(k) Clearance)

Jan 2017
Decision
72d
Days
Class 1
Risk

K162959 is an FDA 510(k) clearance for the LIAISON® EA IgG and LIAISON® EA IgG Serum Control Set. This device is classified as a Epstein-barr Virus, Other (Class I - General Controls, product code LSE).

Submitted by DiaSorin, Inc. (Stillwater, US). The FDA issued a Cleared decision on January 4, 2017, 72 days after receiving the submission on October 24, 2016.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.3235.

Submission Details

510(k) Number K162959 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 24, 2016
Decision Date January 04, 2017
Days to Decision 72 days
Submission Type Special
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code LSE — Epstein-barr Virus, Other
Device Class Class I - General Controls
CFR Regulation 21 CFR 866.3235